Bioventus Announces Purchase of Exclusive Rights to Pfizer's BMP Portfolio

Bioventus, a leader in active orthopaedic healing, today announced agreement with Pfizer Inc. (NYSE: PFE ) for an exclusive, worldwide license to Pfizer's bone morphogenetic protein (BMP) portfolio of development programs and associated intellectual property. The portfolio includes a next-generation BMP in development, designed to offer additional options to currently-marketed BMP products, and the